Neuland Laboratories Beheer
Beheer criteriumcontroles 2/4
De CEO Neuland Laboratories is Davuluri Rao, benoemd in Aug2013, heeft een ambtstermijn van 11.25 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 148.30M, bestaande uit 16.3% salaris en 83.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.3% van de aandelen van het bedrijf, ter waarde ₹ 6.81B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 9.5 jaar.
Belangrijke informatie
Davuluri Rao
Algemeen directeur
₹148.3m
Totale compensatie
| Percentage CEO-salaris | 16.3% |
| Dienstverband CEO | 11.3yrs |
| Eigendom CEO | 3.3% |
| Management gemiddelde ambtstermijn | 4.2yrs |
| Gemiddelde ambtstermijn bestuur | 9.5yrs |
Recente managementupdates
Recent updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14
Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹3b |
| Mar 31 2024 | ₹148m | ₹24m | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹2b |
| Mar 31 2023 | ₹58m | ₹20m | ₹2b |
| Dec 31 2022 | n/a | n/a | ₹1b |
| Sep 30 2022 | n/a | n/a | ₹831m |
| Jun 30 2022 | n/a | n/a | ₹651m |
| Mar 31 2022 | ₹30m | ₹15m | ₹638m |
| Dec 31 2021 | n/a | n/a | ₹593m |
| Sep 30 2021 | n/a | n/a | ₹731m |
| Jun 30 2021 | n/a | n/a | ₹742m |
| Mar 31 2021 | ₹34m | ₹11m | ₹806m |
| Dec 31 2020 | n/a | n/a | ₹540m |
| Sep 30 2020 | n/a | n/a | ₹384m |
| Jun 30 2020 | n/a | n/a | ₹257m |
| Mar 31 2020 | ₹22m | ₹10m | ₹162m |
| Dec 31 2019 | n/a | n/a | ₹321m |
| Sep 30 2019 | n/a | n/a | ₹257m |
| Jun 30 2019 | n/a | n/a | ₹216m |
| Mar 31 2019 | ₹13m | ₹10m | ₹164m |
| Mar 31 2018 | ₹5m | ₹3m | ₹121m |
Compensatie versus markt: De totale vergoeding ($USD 1.76M ) Davuluri } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 610.84K ).
Compensatie versus inkomsten: De vergoeding van Davuluri is het afgelopen jaar met meer dan 20% gestegen.
CEO
Davuluri Rao (49 yo)
11.3yrs
Tenure
₹148,300,000
Compensatie
Mr. Davuluri Sucheth Rao has been the Chief Executive Officer of Neuland Laboratories Limited since August 1, 2013, where Mr. Rao also served as its Chief Operating Officer. At Neuland, Sucheth has been re...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman & Chief Promoter and Member of Scientific Advisory Board | 40.8yrs | ₹148.50m | 26.37% ₹ 54.4b | |
| Vice Chairman & CEO | 11.3yrs | ₹148.30m | 3.3% ₹ 6.8b | |
| Vice Chairman & MD | 15.4yrs | ₹148.30m | 2.24% ₹ 4.6b | |
| Chief Financial Officer | 2yrs | geen gegevens | geen gegevens | |
| Chief Scientific Officer & Member of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Company Secretary & Compliance Officer | 12.8yrs | geen gegevens | geen gegevens | |
| Senior VP of Global Head Sales & BD | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Global API Sales | no data | geen gegevens | geen gegevens | |
| Chief Procurement Officer | no data | ₹6.81m | geen gegevens | |
| President of Business Development & Contract Manufacturing | no data | geen gegevens | geen gegevens | |
| Chief Quality Officer | less than a year | geen gegevens | geen gegevens |
4.2yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NEULANDLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman & Chief Promoter and Member of Scientific Advisory Board | 40.8yrs | ₹148.50m | 26.37% ₹ 54.4b | |
| Vice Chairman & CEO | 21.3yrs | ₹148.30m | 3.3% ₹ 6.8b | |
| Vice Chairman & MD | 15.4yrs | ₹148.30m | 2.24% ₹ 4.6b | |
| Chief Scientific Officer & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 2yrs | ₹2.90m | 0.00062% ₹ 1.3m | |
| Non-Executive Independent Director | 5.8yrs | ₹3.24m | geen gegevens | |
| Independent Director | 1.3yrs | ₹2.82m | geen gegevens | |
| Non-Executive Director & Member of Scientific Advisory Board | 15.1yrs | ₹2.85m | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Non-Executive Independent Director | 9.5yrs | ₹3.16m | geen gegevens | |
| Independent Director | 1.3yrs | ₹2.82m | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
9.5yrs
Gemiddelde duur
78yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NEULANDLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).